Healthcare · 13.1

Pharmaceuticals

Quantified news impact based on deduplicated, quality-reviewed events in a single 200-day window.

Average net impact+26weighted per event

Average gross impact31absolute weighted average

Events25same period

Confidence81%model average

Raw intensity60before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed0.1 / day

Concentration5%

Direction disagreement17%

Source independence98%14 sources

IMPACT TREND

200-day effective impact

Positive 21 · Negative 2 · Mixed 2

+260-26

15 Jan0 events

1 Feb0 events

18 Feb0 events

6 Mar0 events

23 Mar0 events

9 Apr0 events

25 Apr0 events

12 May0 events

29 May0 events

14 Jun0 events

1 Jul0 events

+26

18 Jul25 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term46%361 cumulative effective impact

Medium term47%365 cumulative effective impact

Long term7%52 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 2 of 3 · 25 events

Macro3

Macro27 Jul, 10:52positive

Guangzhou H1 2025 GDP Up 5.8%, IC Manufacturing Jumps 73.9%, NEV Output Rises 53.2%

In the first half of 2025, Guangzhou's gross domestic product grew 5.8% year-on-year to RMB 1,604.5 billion, the highest half-year growth rate since 2022. The primary sector added value of RMB 10.8 billion, up 3.2%; the secondary sector rose 5.6%; and the tertiary sector grew 5.9%. Among first-tier cities, Guangzhou tied with Shenzhen for the fastest growth. Industrial production improved significantly, with integrated circuit manufacturing value added surging 73.9% and new energy vehicle output increasing 53.2%. Fixed-asset investment rose 6.1%, and high-tech manufacturing investment grew 29.5%.

Effective: +27
Intensity: 50
Confidence: 70%
Horizon: Medium term

Macro29 Jul, 18:34positive

Shanghai Guotou Xian Dao Fund: 900 Billion Yuan Mother Funds Invest 565 Billion Yuan

At the 2026 Science and Technology Innovation Industry Integration Development Conference, Wen Zhi, General Manager of Shanghai Guotou Xian Dao Fund, stated that the three major leading industry mother funds total RMB 900 billion, with cumulative investment decisions of RMB 565 billion and disbursements of RMB 340 billion, leveraging over RMB 2.5 trillion in social capital. Direct investments exceed 70% into early-stage and small enterprises, while 55 sub-funds allocate over 80% to such projects. Wen Zhi outlined four practices addressing the challenges of early-stage investing, supported by policies from 2025 and 2026.

Effective: +25
Intensity: 50
Confidence: 75%
Horizon: Long term

Macro27 Jul, 16:51positive

Hong Kong Q2 2026 Ad Spend Rises 5% to HK$8.77 Billion, World Cup Boosts June by 9%

Hong Kong's advertising expenditure in the second quarter of 2026 reached HK$8.77 billion, up 5% year-on-year. Monthly growth was 5% in April, 2% in May and 9% in June, driven by the World Cup. Social media led ad spending, followed by TV, mobile, search engine marketing and outdoor advertising. Magazine ads rose 22%. The banking, credit card and investment services sector saw a 19% increase, with HSBC and Hang Seng Bank posting 15% and 52% growth respectively. Insurance jumped 56% from 13th to 8th place.

Effective: +17
Intensity: 40
Confidence: 70%
Horizon: Short term

Industries3

Industries29 Jul, 20:43positive

China's Pharmaceutical Distribution Market Reaches 1.54 Trillion RMB in First Half of 2026, Up 4%

In the first half of 2026, China's pharmaceutical distribution industry recorded a market size of about 1.54 trillion RMB, up approximately 4% year on year. The sector is accelerating its transformation toward intensification and specialization. High-end cold chain logistics has emerged as a profit growth driver, with leading enterprises deploying multi-temperature zone smart warehouses nationwide. As digital and intelligent upgrades become widespread, AI scheduling, unmanned warehouses, and full-chain temperature and humidity tracking have become standard.

Effective: +28
Intensity: 60
Confidence: 80%
Horizon: Short term

Industries27 Jul, 21:15positive

China Issues TCM Revitalization Plan; Drug Registration Approvals and Medical Services Index Surge 4%

A-share medical services index rose over 4% on July 27 as multiple drug firms, including ST Wanbang, received registration certificates. Wanbang Pharmaceutical surged over 13%, while several other stocks gained over 6%. The National Administration of Traditional Chinese Medicine and the National Development and Reform Commission issued the 15th Five-Year Plan for TCM revitalization, covering the 2026-2030 period.

Effective: +24
Intensity: 50
Confidence: 80%
Horizon: Short term

Industries27 Jul, 21:07negative

China Revises Ganmaoling Instructions, Adds Driving Ban; Huaren Sanjiu 999 Sales Top RMB 2 Billion in 2025

China's National Medical Products Administration has revised the instructions for Ganmaoling oral liquid preparations, adding warnings including a ban on driving and operating precision instruments. Manufacturers must file updated instructions with provincial drug authorities by October 15, 2026. Huaren Sanjiu's 999 Ganmaoling brand recorded retail sales exceeding RMB 2 billion in 2025. In a related court case, a pharmacy was found 40% liable for dispensing drugs without proper instructions, highlighting the importance of compliance.

Effective: -18
Intensity: 40
Confidence: 80%
Horizon: Short term

Companies4

Companies27 Jul, 16:47positive

Hengrui Medicine's SHR-4375 Injection Gets FDA Orphan Drug Designation for Pancreatic Cancer

Hengrui Medicine announced on July 27 that its SHR-4375 injection has received orphan drug designation from the U. S. Food and Drug Administration for the treatment of pancreatic cancer. Orphan drugs are intended for rare diseases, and the designation may provide development incentives.

Effective: +27
Intensity: 60
Confidence: 80%
Horizon: Short term

Companies27 Jul, 17:13positive

China Biopharmaceutical and Tempo Scan Form Indonesia JV, China Holds 51% Stake

China Biopharmaceutical has signed a joint venture agreement with Indonesia-listed Tempo Scan to establish PT Tempo CTTQ Biopharmaceutical Indonesia (TCBI). China Biopharmaceutical holds a 51% stake, with Tempo Scan holding 49%. TCBI will combine Tempo Scan's local expertise with China Biopharmaceutical's R&D strengths to focus on drug registration, clinical development, and commercialization. Several products have received local regulatory approval or are under review, with the first specialty drugs expected to launch after regulatory clearance and operational preparations.

Effective: +27
Intensity: 55
Confidence: 85%
Horizon: Long term

Companies27 Jul, 16:44positive

Hengrui Unit Gets NMPA Approval for HRS-1780 Phase II/III Trial in Uncontrolled or Resistant Hypertension

Hengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical has received approval from the National Medical Products Administration to conduct Phase II/III clinical trials for HRS-1780 tablets, a mineralocorticoid receptor antagonist for treating uncontrolled or resistant hypertension. The project has accumulated R&D investment of about RMB 100 million. No similar product is currently on the market in China.

Effective: +26
Intensity: 60
Confidence: 70%
Horizon: Medium term

Companies27 Jul, 23:08positive

FedEx Launches Life Sciences Unit Focused on GLP-1 and Temperature-Controlled Medical Logistics

FedEx launched FedEx Life Sciences in 2026, focusing on healthcare logistics. The unit generates about $10 billion in annual revenue, over 10% of total. Chief Customer Officer Brie Carere said the medical logistics market opportunity is about $80 billion, with 7% CAGR, including 20% growth for GLP-1 drugs and 25% for cell and gene therapies. FedEx uses five temperature zones and real-time tracking; 40% of medical clients use FedEx Surround. Competitor UPS invested $48 million in its network, reporting $11.2 billion in medical revenue. FedEx CEO Raj Subramanian said nearly half of revenue growth is from B2B. FedEx targets $98 billion revenue by 2029.

Effective: +19
Intensity: 40
Confidence: 70%
Horizon: Medium term